CA2200991C - Compounds for the suppression of hiv tat transactivation - Google Patents

Compounds for the suppression of hiv tat transactivation Download PDF

Info

Publication number
CA2200991C
CA2200991C CA002200991A CA2200991A CA2200991C CA 2200991 C CA2200991 C CA 2200991C CA 002200991 A CA002200991 A CA 002200991A CA 2200991 A CA2200991 A CA 2200991A CA 2200991 C CA2200991 C CA 2200991C
Authority
CA
Canada
Prior art keywords
compound
structural formula
following structural
ch3o
ndga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002200991A
Other languages
English (en)
French (fr)
Other versions
CA2200991A1 (en
Inventor
Ru Chih Huang
John N. Gnabre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2200991A1 publication Critical patent/CA2200991A1/en
Application granted granted Critical
Publication of CA2200991C publication Critical patent/CA2200991C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CA002200991A 1994-09-30 1995-09-22 Compounds for the suppression of hiv tat transactivation Expired - Fee Related CA2200991C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/316,341 1994-09-30
US08/316,341 US6365787B1 (en) 1994-09-30 1994-09-30 Compounds for the suppression of HIV TAT transactivation
PCT/US1995/011779 WO1996010549A1 (en) 1994-09-30 1995-09-22 Compounds for the suppression of hiv tat transactivation

Publications (2)

Publication Number Publication Date
CA2200991A1 CA2200991A1 (en) 1996-04-11
CA2200991C true CA2200991C (en) 2007-07-10

Family

ID=23228649

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002200991A Expired - Fee Related CA2200991C (en) 1994-09-30 1995-09-22 Compounds for the suppression of hiv tat transactivation

Country Status (10)

Country Link
US (4) US6365787B1 (2)
EP (1) EP0783474B1 (2)
JP (2) JP3966900B2 (2)
CN (2) CN100413835C (2)
AT (1) ATE403635T1 (2)
AU (1) AU700481B2 (2)
CA (1) CA2200991C (2)
DE (1) DE69535804D1 (2)
ES (1) ES2312168T3 (2)
WO (1) WO1996010549A1 (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
WO1999017609A1 (en) * 1997-10-07 1999-04-15 Larreacorp, Ltd. Nontoxic extract of larrea tridentata and method of making the same
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US20030219407A1 (en) * 2002-05-15 2003-11-27 The Regents Of The University Of California RNA silencing in animals as an antiviral defense
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
US7728036B2 (en) 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
AU2004249124A1 (en) * 2003-05-20 2004-12-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
EP1845787B1 (en) * 2005-01-27 2015-04-15 Erimos Pharmaceuticals LLC Formulations for injection of catecholic butanes, including ndga compounds, into animals
CN101150955B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 递送包括ndga化合物的儿茶酚丁烷的口服制剂
KR20090006062A (ko) * 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 인플루엔자 바이러스 감염의 치료 방법
EP2076252B1 (en) * 2006-10-02 2014-04-02 Erimos Pharmaceuticals LLC Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
NZ581837A (en) * 2007-05-11 2012-08-31 Convatec Technologies Inc Stoma seal coupling including stoma seal support
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
WO2010054264A1 (en) * 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
US20130331414A1 (en) * 2011-01-10 2013-12-12 Susana Valente Inhibitors of Retroviral Replication
US9877978B2 (en) 2012-02-03 2018-01-30 The Johns Hopkins University Compositions comprising NDGA derivatives and sorafenib and their use in treatment of cancer
WO2014015136A2 (en) * 2012-07-18 2014-01-23 The Johns Hopkins University Methods for inhibition of bnip3 and prevention and treatment of ischemia reperfusion injury by tetra-o-methyl nordihydroguaiaretic acid
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276060A (en) * 1979-06-19 1994-01-04 Block/Chemex, G.P. Methods of treating tumors with compositions of catecholic butanes
US5008294A (en) 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (de) 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
US4774229A (en) 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
US4880637A (en) * 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
FR2632956B2 (fr) * 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5559149A (en) 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5195965A (en) * 1991-03-07 1993-03-23 Shantha Totada R Method and apparatus for localized treatment of human viral infections and cancers
US5646186A (en) 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6071949A (en) 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en) * 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
DE69739105D1 (de) 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N

Also Published As

Publication number Publication date
EP0783474A1 (en) 1997-07-16
ES2312168T3 (es) 2009-02-16
US5663209A (en) 1997-09-02
WO1996010549A1 (en) 1996-04-11
US6291524B1 (en) 2001-09-18
CN1762951A (zh) 2006-04-26
EP0783474A4 (2) 1997-08-27
DE69535804D1 (de) 2008-09-18
EP0783474B1 (en) 2008-08-06
CN1211335C (zh) 2005-07-20
AU3633995A (en) 1996-04-26
CN100413835C (zh) 2008-08-27
JP2006273869A (ja) 2006-10-12
JP3966900B2 (ja) 2007-08-29
ATE403635T1 (de) 2008-08-15
CN1162301A (zh) 1997-10-15
USRE40246E1 (en) 2008-04-15
JPH10509421A (ja) 1998-09-14
US6365787B1 (en) 2002-04-02
AU700481B2 (en) 1999-01-07
CA2200991A1 (en) 1996-04-11

Similar Documents

Publication Publication Date Title
US5663209A (en) Compounds for the suppression of HIV Tat transactivation
WO1996010549A9 (en) Compounds for the suppression of hiv tat transactivation
Gnabre et al. Isolation of anti-HIV-1 lignans from Larrea tridentata by counter-current chromatography
KR101567633B1 (ko) 감귤 미성숙과 추출물, 또는 시네프린 또는 이의 염을 유효성분으로 포함하는 염증성 피부질환 치료 또는 예방용 조성물
KR20050025588A (ko) 올리브 식물수로부터의 히드록시티로졸-풍부 조성물 및그의 사용 방법
US10143673B2 (en) Active fraction of a polar solvent extract from the latex of euphorbiaceae plants
US6586021B2 (en) Method for extraction and purification of biologically useful molecules from a mangrove plant Salvadora persica L
US6923993B2 (en) Process of isolating extract from the Euphorbia obesa plant and methods for using the same
KR100191901B1 (ko) 새로운 세스퀴테르펜 에스테르 화합물
US20050238737A1 (en) Use of one or more shogaol(s) as an aphrodisiac
US5989555A (en) Extracts of Larrea tridentata having antiviral activity and their use for treating viral infections
Basak et al. Comparative appraisal of piperine content in various female spikes of Piper longum Linn., a RET medicinal plant of Odisha.
US5928645A (en) Extracted substance having anti-HIV activity
AU2005202105B2 (en) Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora Persica L.
JP2003073292A (ja) 新規コレステロール合成阻害剤
AU2001256653B2 (en) Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L.
JPH03287527A (ja) 発癌予防剤
HK1090023A (en) Compounds for the suppression of hiv tat transactivation
Arunachalam et al. Comparative botanical and phytochemical studies of ambiguous medicinal plant species of Wedelia and Eclipta (Fam. Asteraceae) used in ASU systems of medicine with special reference to in-silico screening of hepatoprotective potential of marker wedelolactone with acetaminophen targets.
WO2024189591A1 (en) Herbal composition for treatment of hiv
JPH06329537A (ja) 肺癌抑制剤
INVITÉ Abdelgadir A. ABDELGADIR
JP2003277257A (ja) 発癌予防剤
AU2001256653A1 (en) Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed